000			02982nam a22003497a 4500
008			190314s20192019 xxu||||| |||| 00| 0 eng d
022			_a2471-254X
024			_a10.1002/hep4.1304 [doi]
024			_aHEP41304 [pii]
024			_aPMC6357828 [pmc]
040			_aOvid MEDLINE(R)
099			_a30766960
245			_aDevelopment of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma.
251			_aHepatology Communications. 3(2):220-226, 2019 Feb.
252			_aHepatol. commun.. 3(2):220-226, 2019 Feb.
253			_aHepatology communications
260			_c2019
260			_fFY2019
265			_sepublish
266			_d2019-03-14
520			_aNonalcoholic fatty liver disease is the most common liver disorder in the developed world. Although typically reflecting caloric overload, it can also be secondary to drug toxicity. We aimed to describe the incidence and risk factors for de novo steatosis during chemotherapy for non-Hodgkin lymphoma (NHL). In this retrospective case-control study, adult patients with NHL were treated with rituximab, cyclophosphamide, doxorubicin, prednisone, and vincristine (R-CHOP) or R-CHOP + etoposide (EPOCH-R). Patients with liver disease or steatosis were excluded. Abdominal computed tomography was performed pretreatment and at 3- to 6-month intervals and reviewed for steatosis. Patients with de novo steatosis were matched 1:1 to controls by age, sex, and ethnicity. Of 251 treated patients (median follow-up 53 months), 25 (10%) developed de novo steatosis, with the vast majority (23 of 25; 92%) developing it after chemotherapy. Of those, 14 (61%) developed steatosis within the first 18 months posttreatment and 20 (87%) within 36 months. Cases had higher baseline body mass index (BMI; mean +/- SD, 29.0 +/- 6.5 versus 26.0 +/- 5.2 kg/m<sup>2</sup>; P = 0.014) and hyperlipidemia (12% versus 2%; P = 0.035). Although their weights did not change during chemotherapy, BMI in cases increased by 2.4 +/- 2 kg/m<sup>2</sup> (mean +/- SD) from end of treatment to steatosis compared to 0.68 +/- 1.4 in controls (P = 0.003). Etoposide-containing regimens were associated with a shorter time to steatosis (median 34 weeks versus 154 weeks; P < 0.001) despite similar baseline risk factors. Conclusion: The recovery period from NHL chemotherapy appears to be a "hot spot" for development of fatty liver, driven by early posttreatment weight gain, especially in subjects with baseline risk factors.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Washington Hospital Center
656			_aMedicine/General Internal Medicine
657			_aJournal Article
700			_aCho, Min Ho
700			_aHemmati, Mehdi
790			_aAlao H, Ben-Yakov G, Cho MH, Dunleavy K, Fryzek N, Haydek JP, Hemmati M, Jones EC, Rotman Y, Samala V, Shovlin M, Wilson W
856			_uhttps://dx.doi.org/10.1002/hep4.1304 _zhttps://dx.doi.org/10.1002/hep4.1304
942			_cART _dArticle
999			_c4145 _d4145